Moving Care Forward in Advanced Gastric Cancer

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Immune Checkpoint Inhibition

ICIs Approved for G/GEJ Cancers

MSI-H/dMMR Tumors

MSI-H/dMMR in Second-Line Setting Pembrolizumab

MSI-H/dMMR in Second-Line Setting Nivolumab

What Does PD-L1 Positive Mean?

Pembrolizumab for PD-L1-Positive in Third-Line Setting KEYNOTE-059

Nivolumab for PD-L1-Positive in Third-Line Setting ATTRACTION-2

Practical Implications -- Deciding Who to Treat

Other Biomarkers

Immune-Related Adverse Events

Practical Implications Managing irAEs

Pembrolizumab in G/GEJ -- Negative Trial KEYNOTE-061

Avelumab in G/GEJ -- Negative Trial Javelin Gastric 300

Pembrolizumab for Esophageal Cancer in Third-Line KEYNOTE-180

Pembrolizumab for Esophageal Cancer in Second-Line KEYNOTE-181

Implications of Results

Immunotherapy Plus Chemotherapy First-Line Setting

Future Phase 3 Trials First-Line Setting

Future Phase 3 Trials First-Line Setting (cont)

Future Trials The Adjuvant and Neoadjuvant Settings

Future Trials The Adjuvant and Neoadjuvant Settings (cont)

IO-IO Combination Therapy CheckMate-032

Ongoing Research Combination IO-IO

Ongoing Research Immunotherapy With VEGFR2 Inhibitor

Ongoing Research Immunotherapy With HER2 Inhibitors

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)